Stifel Downgrades Ra Pharma (RARX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 7, 2019 7:00 AM ESTFirst patient dosed in the global, pivotal, Phase 3 RAISE study of zilucoplan in gMG, with top-line results expected in early 2021
On track to dose first patient in the Phase 2 trial of zilucoplan in immune-mediated necrotizing myopathy (IMNM) by year-end 2019
Zilucoplan selected by leading experts as one of the first therapeutic candidates to enter the HEALEY ALS Platform Trial at Mass General
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
... More